Abstract: Provided herein are co-crystal forms comprising 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one (VX-745): and compositions thereof, useful as inhibitors of one or more protein kinases and which exhibit desirable characteristics for the same.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
October 11, 2022
Assignee:
EIP Pharma, LLC
Inventors:
John Jahangir Alam, Jeffrey Douglas Wilson
Abstract: Provided herein are co-crystal forms, and compositions thereof, useful as inhibitors of one or more protein kinases and which exhibit desirable characteristics for the same.
Abstract: Disclosed are oral pharmaceutical compositions of neflamapimod that exhibit suitable exposure for administration in humans and/or that maintain a desirable dissolution profile under standard storage conditions.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
May 19, 2020
Assignee:
EIP Pharma, LLC
Inventors:
John Jahangir Alam, Jeffrey Douglas Wilson
Abstract: The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.
Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.
Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.
Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.
Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.